Annual CFO
-$101.23 M
-$4.51 M-4.66%
December 31, 2022
Summary
- As of February 8, 2025, EVLO annual cash flow from operations is -$101.23 million, with the most recent change of -$4.51 million (-4.66%) on December 31, 2022.
- During the last 3 years, EVLO annual CFO has fallen by -$29.25 million (-40.64%).
- EVLO annual CFO is now -722.11% below its all-time high of -$12.31 million, reached on December 31, 2016.
Performance
EVLO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$10.41 M
+$9.42 M+47.51%
September 30, 2023
Summary
- As of February 8, 2025, EVLO quarterly cash flow from operations is -$10.41 million, with the most recent change of +$9.42 million (+47.51%) on September 30, 2023.
- Over the past year, EVLO quarterly CFO has increased by +$12.18 million (+53.92%).
- EVLO quarterly CFO is now -138.88% below its all-time high of -$4.36 million, reached on March 31, 2017.
Performance
EVLO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$73.70 M
+$12.18 M+14.18%
September 30, 2023
Summary
- As of February 8, 2025, EVLO TTM cash flow from operations is -$73.70 million, with the most recent change of +$12.18 million (+14.18%) on September 30, 2023.
- Over the past year, EVLO TTM CFO has increased by +$32.19 million (+30.40%).
- EVLO TTM CFO is now -1591.55% below its all-time high of -$4.36 million, reached on March 31, 2017.
Performance
EVLO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
EVLO Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4.7% | +53.9% | +30.4% |
| 3 y3 years | -40.6% | +42.9% | -0.8% |
| 5 y5 years | -335.1% | +17.8% | -2.4% |
EVLO Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -4.7% | at low | at high | +64.0% | at high | +33.3% |
| 5 y | 5-year | -40.6% | at low | at high | +64.0% | -2.4% | +33.3% |
| alltime | all time | -722.1% | at low | -138.9% | +64.0% | -1591.5% | +33.3% |
Evelo Biosciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | -$10.41 M(-47.5%) | -$73.70 M(-14.2%) |
| Jun 2023 | - | -$19.83 M(-2.2%) | -$85.88 M(-7.2%) |
| Mar 2023 | - | -$20.28 M(-12.6%) | -$92.58 M(-8.6%) |
| Dec 2022 | -$101.23 M(+4.7%) | -$23.19 M(+2.7%) | -$101.23 M(-4.4%) |
| Sep 2022 | - | -$22.59 M(-14.8%) | -$105.89 M(-4.1%) |
| Jun 2022 | - | -$26.53 M(-8.3%) | -$110.47 M(+11.2%) |
| Mar 2022 | - | -$28.93 M(+3.9%) | -$99.38 M(+2.7%) |
| Dec 2021 | -$96.72 M(+32.4%) | -$27.85 M(+2.5%) | -$96.72 M(+10.1%) |
| Sep 2021 | - | -$27.17 M(+76.0%) | -$87.83 M(+11.3%) |
| Jun 2021 | - | -$15.43 M(-41.3%) | -$78.88 M(-1.2%) |
| Mar 2021 | - | -$26.28 M(+38.7%) | -$79.83 M(+9.3%) |
| Dec 2020 | -$73.06 M | -$18.95 M(+4.0%) | -$73.06 M(-0.1%) |
| Sep 2020 | - | -$18.22 M(+11.3%) | -$73.10 M(-1.9%) |
| Jun 2020 | - | -$16.38 M(-16.1%) | -$74.52 M(+1.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$19.52 M(+2.7%) | -$73.50 M(+2.1%) |
| Dec 2019 | -$71.98 M(+52.2%) | -$18.99 M(-3.3%) | -$71.98 M(+5.2%) |
| Sep 2019 | - | -$19.64 M(+27.9%) | -$68.44 M(+11.4%) |
| Jun 2019 | - | -$15.36 M(-14.7%) | -$61.47 M(+7.9%) |
| Mar 2019 | - | -$17.99 M(+16.4%) | -$56.96 M(+20.5%) |
| Dec 2018 | -$47.28 M(+103.2%) | -$15.46 M(+22.1%) | -$47.28 M(+19.5%) |
| Sep 2018 | - | -$12.66 M(+16.7%) | -$39.55 M(+21.5%) |
| Jun 2018 | - | -$10.85 M(+30.4%) | -$32.56 M(+19.6%) |
| Mar 2018 | - | -$8.32 M(+7.6%) | -$27.22 M(+17.0%) |
| Dec 2017 | -$23.27 M(+88.9%) | -$7.73 M(+36.2%) | -$23.27 M(+49.7%) |
| Sep 2017 | - | -$5.67 M(+3.0%) | -$15.54 M(+57.5%) |
| Jun 2017 | - | -$5.51 M(+26.4%) | -$9.87 M(+126.4%) |
| Mar 2017 | - | -$4.36 M | -$4.36 M |
| Dec 2016 | -$12.31 M | - | - |
FAQ
- What is Evelo Biosciences annual cash flow from operations?
- What is the all time high annual CFO for Evelo Biosciences?
- What is Evelo Biosciences annual CFO year-on-year change?
- What is Evelo Biosciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Evelo Biosciences?
- What is Evelo Biosciences quarterly CFO year-on-year change?
- What is Evelo Biosciences TTM cash flow from operations?
- What is the all time high TTM CFO for Evelo Biosciences?
- What is Evelo Biosciences TTM CFO year-on-year change?
What is Evelo Biosciences annual cash flow from operations?
The current annual CFO of EVLO is -$101.23 M
What is the all time high annual CFO for Evelo Biosciences?
Evelo Biosciences all-time high annual cash flow from operations is -$12.31 M
What is Evelo Biosciences annual CFO year-on-year change?
Over the past year, EVLO annual cash flow from operations has changed by -$4.51 M (-4.66%)
What is Evelo Biosciences quarterly cash flow from operations?
The current quarterly CFO of EVLO is -$10.41 M
What is the all time high quarterly CFO for Evelo Biosciences?
Evelo Biosciences all-time high quarterly cash flow from operations is -$4.36 M
What is Evelo Biosciences quarterly CFO year-on-year change?
Over the past year, EVLO quarterly cash flow from operations has changed by +$12.18 M (+53.92%)
What is Evelo Biosciences TTM cash flow from operations?
The current TTM CFO of EVLO is -$73.70 M
What is the all time high TTM CFO for Evelo Biosciences?
Evelo Biosciences all-time high TTM cash flow from operations is -$4.36 M
What is Evelo Biosciences TTM CFO year-on-year change?
Over the past year, EVLO TTM cash flow from operations has changed by +$32.19 M (+30.40%)